BEIJING STRONG BIOTECHNOLOGIES,INC. Beijing Strong Biotechnologies,Inc. Stock
Equities
300406
CNE100001Y26
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.75 CNY | +1.66% |
|
+3.98% | -7.07% |
| Sales 2024 * | 2.05B 283M | Sales 2025 * | 2.43B 335M | Capitalization | 10.41B 1.44B |
|---|---|---|---|---|---|
| Net income 2024 * | 618M 85.29M | Net income 2025 * | 769M 106M | EV / Sales 2024 * | 5.08 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.29 x |
| P/E ratio 2024 * |
16.9
x | P/E ratio 2025 * |
13.5
x | Employees | 1,094 |
| Yield 2024 * |
1.35% | Yield 2025 * |
1.63% | Free-Float | 38.97% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.66% | ||
| 1 week | +3.98% | ||
| Current month | -8.03% | ||
| 1 month | -6.87% | ||
| 3 months | -7.84% | ||
| 6 months | +8.17% | ||
| Current year | -7.07% |
1 week
16.79
17.77
1 month
16.7819.52
Current year
16.0021.78
1 year
16.0024.80
3 years
12.5025.59
5 years
12.1525.73
10 years
4.5941.94
| Managers | Title | Age | Since |
|---|---|---|---|
Xi Liu
FOU | Founder | 62 | 01-03-28 |
Wei Liu
DFI | Director of Finance/CFO | 55 | 06-12-31 |
Dan Sheng
BRD | Director/Board Member | 47 | 16-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Lei Fu
BRD | Director/Board Member | 73 | 17-04-17 |
Yong Hong Chen
BRD | Director/Board Member | 62 | 20-08-12 |
Zuo Jun Zou
FOU | Founder | 66 | 01-03-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 17.75 | +1.66% | 6,979,024 |
| 24-04-25 | 17.46 | +1.57% | 11,116,920 |
| 24-04-24 | 17.19 | -0.64% | 5,370,273 |
| 24-04-23 | 17.3 | -0.69% | 5,151,073 |
| 24-04-22 | 17.42 | +2.05% | 8,167,398 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
Beijing Strong Biotechnologies Inc. is a China-based company mainly engaged in the research and development, manufacture and sales of in vitro diagnostic reagents. The Companyâs in vitro diagnostic reagents are mainly used in liver, renal, blood fat, glycometabolism and other fields. The Company is also engaged in the manufacture and sales of in vitro diagnostic equipment and the leasing of equipment. The Company operates businesses in domestic and overseas markets.
Calendar
2024-04-28
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
17.75
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -7.07% | 1.44B | |
| +0.89% | 12.8B | |
| -10.29% | 7.61B | |
| +1.78% | 5.41B | |
| -1.16% | 4.51B | |
| +5.74% | 4.49B | |
| -50.70% | 3.29B | |
| +12.21% | 2.73B | |
| -16.13% | 2.02B | |
| -11.50% | 1.73B |
- Stock Market
- Equities
- 300406 Stock
